普瑞巴林联合超激光照射治疗糖尿病神经病理性疼痛的临床疗效观察  

THE CLINICAL EFFECTS OF SUPERLiZER IRRADIATION COMBINED WITH PREGABALIN ON THE TREATMENT OF DIABETIC PAINFUL NEUROPATHY

作　　者：石海梅[1] 贾雅蕊[1] 周华成[1] 刘金锋[1] 

机构地区：[1]哈尔滨医科大学附属第二医院疼痛科,黑龙江麻醉与危重病重点实验室,哈尔滨150086

出　　处：《中国疼痛医学杂志》2012年第4期198-201,共4页Chinese Journal of Pain Medicine

摘　　要：目的:观察普瑞巴林联合超激光照射治疗糖尿病神经病理性疼痛的疗效和安全性。方法:60例下肢糖尿病神经病理性疼痛患者随机均分为普瑞巴林低剂量组(A组,150 mg/d)、普瑞巴林高剂量组(B组,300 mg/d)、低剂量联合超激光照射组(C组)和高剂量联合超激光照射组(D组)。联合组在药物治疗基础上每日行超激光照射一次,4周后停止超激光治疗,各组患者继续按原剂量及方法服用普瑞巴林4周后随访。观察治疗前、治疗2周、4周及8周时疼痛视觉模拟评分(visualanalogue scale,VAS)变化及不良反应。结果:四组患者治疗2周及4周后VAS均明显降低(P<0.05),且B、C两组的VAS评分均较A组低(P<0.05),较D组高(P<0.05);B、C两组VAS评分差异无统计学意义。治疗8周时VAS评分较治疗前明显降低(P<0.05),同剂量普瑞巴林组VAS评分差异无统计学意义。不良反应主要为眩晕和嗜睡。B、D两组总不良反应发生率高于A、C组(P<0.05)。B组和D组,A组和C组比较,总不良反应发生率无统计学差异(P>0.05)。结论:超激光照射可作为普瑞巴林治疗糖尿病神经病理性疼痛的一种辅助手段,近期效果较好。Objective： To evaluate the efficacy and safety of the superliser irradiation with pregabalin in the treatment of diabetic painful neuropathy in patients. Methods： Sixty patients with lower extremity diabetic painful neuropathy were randomly and equally assigned into four groups. Patients in group A and group B took pregabalin 150 mg/d, 300 mg/d orally bid, respectively; In addition to daily irradiation of superliser, patients in group C and group D took pregabalin 150 mg/d, 300 mg/d orally bid, respectively. The course lasted four weeks. Then irradiation was stopped after 4 weeks, and the medicine treatment were continued another 4 weeks. Visual analogue scale （VAS） and the incidence of adverse reactions before and 2, 4, 8 weeks after treatment were observed. Results： VAS score in the four groups after treatment were significantly lower than that before treatment （P 〈 0.05）. VAS score in group B and C was lower than group A （P 〈 0.05）, and was highr than group D （P 〈 0.05）; VAS score was not statistically significant between group B and C. 8 Weeks after treatment, VAS scores was lower than before treatment. VAS scores were not significantly different when pregabalin was taken at a same dose （P 〉 0.05）. Adverse reactions throughout four weeks were mainly dizziness and somnolence. The incidences of adverse reactio- ns in group B and D were higher than those in group A and C （P 〈 0.05）. The total incidences of adverse reactions had no significant difference between group B and D, between group A and C （P 〉 0.05）. Conclusion： The superliser irradiation as a supplementary of pregabalin had a good short-term effect in treatment of diabetic painful neuropathy.

关 键 词：普瑞巴林 超激光照射 糖尿病神经病理性疼痛 

分 类 号：R587.2[医药卫生—内分泌]